Catalyst Biosciences Inc Receives a Buy from Chardan Capital


In a report released today, Gbola Amusa from Chardan Capital maintained a Buy rating on Catalyst Biosciences Inc (NASDAQ: CBIO), with a price target of $35. The company’s shares opened today at $9.19.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 23.7% and a 53.7% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.

Catalyst Biosciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $59.50.

See today’s analyst top recommended stocks >>

Based on Catalyst Biosciences Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.04 million. In comparison, last year the company had a GAAP net loss of $4.14 million.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts